FDA clears synthetic antibodies against Covid

The race to treat Covid-19 takes a new turn with synthetic antibodies. The U.S. Food and Drug Administration (FDA) has just approved a treatment from the Regeneron firm. It involves two monoclonal antibodies administered together in cases of non-severe infection, in order to reduce disease complications and thus hospitalizations.